Which companies overlap with Comprehensive Support Project for Oncology Research's portfolio?

Top competitors by shared drug class: Dana-Farber Cancer Institute, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/comprehensive-support-project-for-oncology-research.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Comprehensive Support Project for Oncology Research — Portfolio Competitive Intelligence Brief

Comprehensive Support Project for Oncology Research pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
trastuzumab and chemotherapy	trastuzumab and chemotherapy	phase 3	HER2-targeted monoclonal antibody + chemotherapy combination	HER2 (human epidermal growth factor receptor 2)	Oncology
trastuzumab monotherapy	trastuzumab monotherapy	phase 3	HER2/neu receptor antagonist	HER2/neu	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dana-Farber Cancer Institute · 1 shared drug class
Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Comprehensive Support Project for Oncology Research:

Cite this brief

Drug Landscape (2026). Comprehensive Support Project for Oncology Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/comprehensive-support-project-for-oncology-research. Accessed 2026-05-16.